Genetic testing confirmed the autosomal dominant polycystic kidney disease (ADPKD) diagnosis with a PKD1 gene mutation. Initial laboratory tests indicated a serum creatinine level of 0.70 mg/dL, an estimated glomerular filtration rate (eGFR) of 78 mL/min/1.32 m², and a urinary albumin to creatinine ratio of 63.0 mg/g Cr. Given her age and eGFR exceeding 25 mL/min/1.32 m², an enhanced abdomen computed tomography (CT) was performed to determine the total kidney volume, a prerequisite for initiating tolvaptan therapy. The CT scan revealed an enlarged kidney and liver, with numerous cystic lesions of varying sizes (Fig. 1). Her height-adjusted total kidney volume was 1,163.3 mL/m, classifying her as Mayo class 1D. Consequently, tolvaptan therapy was initiated. The patient’s medical history included her mother’s sudden death. Therefore, a brain magnetic resonance angiography was performed to evaluate cerebral aneurysms, but there was no abnormality. Two years after taking tolvaptan, a follow-up CT was performed, and we found interesting points. On her past CT scan, the right kidney was on the right side beneath the liver, the recent CT scan showed both kidneys on the left side. This displacement of the right kidney was attributed to the increased number and size of hepatic cysts (Fig. 2). Acquired renal displacement can occur due to the enlargement of surrounding organs or the presence of space-occupying lesions within the abdominal cavity. In this case, the patient’s ADPKD and the progressive hepatomegaly resulting from the expanding hepatic cysts led to the right kidney displacement.